CD8A and melanoma: It was discovered that the clinical responses to ICB in patients with melanoma were associated with the presence of stem-like CD8+ T cells with reduced expression of co-inhibitory molecules and elevated memory, activation, and cell survival transcriptional and epigenetic programs compared with exhausted CD8+ T cells [24,25].